If you’ve seen headlines this week about Medicare and weight-loss drugs, you’re not imagining it; it’s a real and pretty significant policy shift.

Starting July 1, 2026, CMS (the agency that runs Medicare) is launching a temporary program called the Medicare GLP-1 Bridge. For the first time in more than 20 years, Medicare will help cover the cost of prescription medication specifically for obesity, giving eligible beneficiaries access to semaglutide, tirzepatide, or orforglipron for around $50 a month through the end of 2027. To qualify, patients generally need to be 18 or older, enrolled in Medicare Part D, and have a BMI of 35+ or a BMI between 27–34.9 with a weight-related health condition.

It’s a big deal for the people it covers. But if you’re not on Medicare or you don’t meet the qualifying criteria, you might be wondering what this means for you.

Whether you’re accessing GLP-1 medication through a new Medicare pathway, private insurance, or a self-pay program like ours, the fundamentals of doing it safely and effectively haven’t changed. GLP-1 therapy works best when it’s:

At AZ Vitality and Wellness, our medical weight loss program is built around exactly that kind of provider-guided, personalized approach, regardless of how you’re paying for it. If you’ve been priced out, denied by insurance, or you’re simply not sure where you fall in all these new coverage rules, our team can walk you through what your options actually look like.

A note on pricing: because coverage and self-pay pricing questions come up often right now, the best next step is a quick call — 602-540-3547 — so we can give you accurate, current answers specific to your situation.

Ready to talk through your options? Schedule a consultation or call/text 602-540-3547.